Read by QxMD icon Read


Eduardo Espinet Coll, Javier Nebreda Durán, Gontrand López-Nava Breviere, Julio Ducóns García, Manuel Rodríguez-Téllez, Javier Crespo García, Carlos Marra-López Valenciano
INTRODUCTION: Bariatric endoscopy includes a series of specific techniques focused on the management of obese patients. As a quality criterion, safety as expressed by a minimal incidence of serious complications is required in addition to efficacy. METHODS: A descriptive, retrospective, multicenter review of the experience recorded at seven hospitals included in the Grupo Español de Endoscopia Bariátrica (GETTEMO) in order to document the incidence, cause, and resolution (including legal consequences) of serious complications reported for each bariatric technique, and according to endoscopist expertise...
March 17, 2017: Revista Española de Enfermedades Digestivas
K S C Gollisch, A Lindhorst, D Raddatz
Many obese people with type 2 diabetes develop non-alcoholic fatty liver disease, which may progress to liver fibrosis. EndoBarrier gastrointestinal liner is an innovative interventional treatment option for type 2 diabetic patients, which could affect diabetes associated liver disease. The aim of this retrospective study was to analyze the effect of 1-year EndoBarrier therapy on liver fibrosis and steatosis. As an indicator of fibrosis, liver stiffness was assessed by liver elastography at baseline, 2 weeks after EndoBarrier implantation and then every 3 months until explantation...
February 2017: Experimental and Clinical Endocrinology & Diabetes
Ulrich Rohde
Bariatric surgery (e.g. Roux-en-Y gastric bypass (RYGB)) has proven the most effective way of achieving sustainable weight losses and remission of type 2 diabetes (T2D). Studies indicate that the effectiveness of RYGB is mediated by an altered gastrointestinal tract anatomy, which in particular favours release of the gut incretin hormone glucagon-like peptide-1 (GLP-1). The EndoBarrier gastrointestinal liner or duodenal-jejunal bypass sleeve (DJBS) is an endoscopic deployable minimally invasive and fully reversible technique designed to mimic the bypass component of the RYGB...
November 2016: Danish Medical Journal
Ulrich Rohde, Cecilie A Federspiel, Peter Vilmann, Ebbe Langholz, Steffen U Friis, Martin Krakauer, Jens F Rehfeld, Jens J Holst, Tina Vilsbøll, Filip K Knop
AIMS: The duodenal-jejunal bypass sleeve ((DJBS) or EndoBarrier Gastrointestinal Liner) induces weight loss in obese subjects and may improve glucose homeostasis in patients with type 2 diabetes (T2D). To explore the underlying mechanisms, we evaluated postprandial physiology including glucose metabolism, gut hormone secretion, gallbladder emptying, appetite and food intake in patients undergoing DJBS treatment. MATERIAL AND METHODS: A total of 10 normal glucose-tolerant (NGT) obese subjects and 9 age-, body weight- and body mass index-matched metformin-treated T2D patients underwent a liquid mixed meal test and a subsequent ad libitum meal test before implantation with DJBS and 1 week (1w) and 26 weeks (26w) after implantation...
February 2017: Diabetes, Obesity & Metabolism
Nuria Vilarrasa, Amador García Ruiz de Gordejuela, Anna Casajoana, Xevi Duran, Silvia Toro, Eduard Espinet, Manoel Galvao, Joan Vendrell, Rafael López-Urdiales, Manuel Pérez, Jordi Pujol
BACKGROUND: The purpose of this study was to evaluate the efficacy and safety of Endobarrier® in grade 1 obese T2DM patients with poor metabolic control and the role of gastro-intestinal hormone changes on the metabolic outcomes. METHODS: Twenty-one patients aged 54.1 ± 9.5 years, diabetes duration 14.8 ± 8.5 years, BMI 33.4 ± 1.9 kg/m(2), and HbA1c 9.1 ± 1.3 %, under insulin therapy, were implanted with Endobarrier®. Fasting concentrations of PYY, ghrelin and glucagon, and AUC for GLP-1 after a standard meal test were determined prior to and at months 1 and 12 after implantation...
March 2017: Obesity Surgery
J Feisthammel, M Blüher, J Mössner, A Hoffmeister
The prevalence of obesity in the population has been increasing for many years. Due to associated comorbidities the treatment of obesity is becoming more important. Conservative treatment alone is often unsuccessful, particularly in cases of severe obesity. In these cases, multimodal therapy in specialized treatment units is warranted. Between conservative treatment and bariatric surgery, interventional endoscopic treatment options also play an increasing role. Nowadays, implantation of gastric balloons and duodenojejunal bypass liners (EndoBarrier) are the most often used endoscopic options...
August 2016: Der Internist
Renato V Soares, Silvana Perretta, Dana Mihaela Ignat, Michel Vix, Lee L Swanstrom
No abstract text is available yet for this article.
December 2016: Gastrointestinal Endoscopy
U Rohde, N Hedbäck, L L Gluud, T Vilsbøll, F K Knop
Compared with bariatric surgery, less invasive and reversible techniques to counteract obesity and type 2 diabetes (T2D) have been developed, including the EndoBarrier Gastrointestinal Liner [duodenal-jejunal bypass sleeve (DJBS)]. We conducted a systematic review and meta-analyses of eligible trials to evaluate the efficacy and safety of the DJBS. Five randomized controlled trials (RCTs; 235 subjects) and 10 observational studies (211 subjects) were included. The risk of bias was evaluated as high in all studies...
March 2016: Diabetes, Obesity & Metabolism
Deepanshu Jain, Shashideep Singhal
Obesity is a rapidly growing pandemic. Scope of pharmacotherapy and bariatric surgery in managing obesity is ever rising. The role of minimally invasive techniques to achieve preoperative weight loss and improve postbariatric surgery outcomes is an area of new interest. The initial experience with endobarrier devices in achieving weight loss among obese subjects has shown promising results. In addition, the impact of these interventions on comorbidities commonly associated with obesity like diabetes mellitus type 2 and hyperlipidemia has further expanded their potential for use in future...
November 2015: Journal of Clinical Gastroenterology
Nitin Kumar
A new paradigm in the treatment of obesity and metabolic disease is developing. The global obesity epidemic continues to expand despite the availability of diet and lifestyle counseling, pharmacologic therapy, and weight loss surgery. Endoscopic procedures have the potential to bridge the gap between medical therapy and surgery. Current primary endoscopic bariatric therapies can be classified as restrictive, bypass, space-occupying, or aspiration therapy. Restrictive procedures include the USGI Primary Obesity Surgery Endolumenal procedure, endoscopic sleeve gastroplasty using Apollo OverStitch, TransOral GAstroplasty, gastric volume reduction using the ACE stapler, and insertion of the TERIS restrictive device...
July 25, 2015: World Journal of Gastrointestinal Endoscopy
Ulrich Rohde, Cecilie A Federspiel, Peter Vilmann, Steffen U Friis, Ebbe Langholz, Tina Vilsbøll, Filip K Knop
No abstract text is available yet for this article.
2015: Endoscopy
Eduardo Espinet-Coll, Jordi Pujol-Gebelli, Amador García-Ruiz-de-Gordejuela, Anna Casajoana-Badia, Javier Nebreda-Durán, Antonio Juan-Creix-Comamala, José Antonio Gómez-Valero, Carmen Vila-Lolo
No abstract text is available yet for this article.
March 2015: Revista Española de Enfermedades Digestivas
Eduardo Guimarães Hourneaux de Moura, Guilherme Sauniti Lopes, Bruno Costa Martins, Ivan Roberto Bonotto Orso, Artur Martins Novaes Coutinho, Suzana Lopes de Oliveira, Paulo Sakai, Manoel dos Passos Galvão-Neto, Marco Aurélio Santo, Marcelo Tatit Sapienza, Ivan Cecconello, Carlos Alberto Buchpiguel
INTRODUCTION: The duodenal-jejunal bypass liner (DJBL) is a promising technique for treating obesity and type 2 diabetes mellitus (T2DM). However, despite promising results, its mechanism of action has not been elucidated. It is thought to promote changes in gastric emptying owing to the neuro-endocrine axis. OBJECTIVE: The aim of this paper was to study DJBL-induced changes in gastric emptying and the relationship of those changes with weight loss and T2DM. METHODS: Twenty-five patients with obesity and T2DM met inclusion criteria...
September 2015: Obesity Surgery
Claudia Läßle, Katharina Laubner, Henning Schwacha, Jochen Seufert, Jodok Matthias Grueneberger, Andreas Fischer, W Konrad Karcz, Ulrich T Hopt, Goran Marjanovic, Simon Kuesters
No abstract text is available yet for this article.
2014: Endoscopy
Ulrich Rohde, Nora Hedbäck, Lise L Gluud, Tina Vilsbøll, Filip K Knop
INTRODUCTION: Obese patients with type 2 diabetes undergoing bariatric surgery experience significant and lasting weight loss and improved glycaemic control. However, bariatric surgical procedures such as Roux-en-Y gastric bypass are irreversible and associated with considerable short-term and long-term risks. The EndoBarrier Gastrointestinal Liner or duodenal-jejunal bypass sleeve (DJBS) is a fully reversible procedure that has been developed to treat obesity and type 2 diabetes. We aim to perform a systematic review and meta-analysis of safety and efficacy of DJBS...
2013: BMJ Open
Parviez Koehestanie, Bark Betzel, Kemal Dogan, Frits Berends, Ignace Janssen, Edo Aarts, Marcel Groenen, Peter Wahab
BACKGROUND: The endoscopically placed duodenal-jejunal bypass liner (DJBL) or EndoBarrier gastrointestinal liner has been designed for the treatment of type 2 diabetes mellitus and simultaneous achievement of weight loss by obese patients. This study was performed to determine the safety, efficacy, and feasibility of delivering the DJBL with the patient under conscious sedation (CS). The primary end points of the study were safety and complications. The secondary end points were delivery time (min), amount of propofol (mg) used, and the total hospital stay (h)...
January 2014: Surgical Endoscopy
Shaneel R Patel, John Mason, Nadey Hakim
No abstract text is available yet for this article.
August 2012: Indian Journal of Surgery
Shaneel R H Patel, David Hakim, John Mason, Nadey Hakim
BACKGROUND: Surgical intervention is now the most effective modality with which to treat severe obesity. There is currently a lack of minimally invasive technology with which we can effectively treat obesity and reverse type 2 diabetes mellitus. The EndoBarrier is a fluoropolymer sleeve that is reversibly fixated to the duodenal bulb and extends 80 cm into the small bowel, usually terminating in the proximal jejunum. This endoscopically inserted device aids weight loss through malabsorption and activating hormonal triggers...
May 2013: Surgery for Obesity and related Diseases: Official Journal of the American Society for Bariatric Surgery
E M H Mathus-Vliegen
The EndoBarrier, an endoscopically delivered duodeno-jejunal bypass device, is a unique concept that starts to ameliorate the symptoms of diabetes mellitus type 2, soon after positioning. Weight-loss results are moderate, with 85% of patients showing a more than 10% excess weight loss in the 12 weeks preoperatively. Sufficient implant training is required, but problems can still occur, e.g., due to a short duodenal bulb length. The stability of the anchors and the tolerability of the device still leave much to be desired...
2012: Nederlands Tijdschrift Voor Geneeskunde
Froukje J Verdam, Paulien R Liedorp, Noëlle Geubbels, Ruben Schouten, Ignace M C Janssen, Ger H Koek, Jan Willem Greve
The prevalence of obesity is increasing worldwide. Its primary treatment consists of lifestyle changes. In severely obese (BMI > 40 kg/m2 or ≥ 35 kg/m2 with comorbidity) patients though, bariatric surgery has been found to be the only way to achieve permanent weight loss. Operations such as the placement of a gastric band or a gastric bypass can, however, lead to complications and necessitate secondary interventions. In search of less invasive treatments, placement of the EndoBarrier duodenal jejunal bypass liner appears to be a promising, safe and effective method for facilitating weight loss...
2012: Nederlands Tijdschrift Voor Geneeskunde
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"